KARISHMA PATEL: Open Payments
NPI 1023734902 · EDISON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$765 in 29 payments from 9 companies in 2025. Trend: 2023 $631 · 2024 $306 · 2025 $765
Food & beverage: $765
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 7 | $186 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 6 | $118 |
| ABBVIE INC. | 7 | $108 |
| Amgen Inc. | 1 | $105 |
| Celgene Corporation | 3 | $52 |
| Lilly USA, LLC | 2 | $36 |
| Eisai Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $17 |
Products named: Symbravo, INGREZZA, UPLIZNA, VYVGART, VYVGART HYTRULO, QULIPTA, ZEPOSIA, UBRELVY.
Industry payments across NJ — which companies pay providers there.
